FDA Extends Comment Period for Generic Drug User Fee Notice

Summary

The Food and Drug Administration (FDA) is extending the comment period for a public meeting notice regarding the development of a generic drug user fee program, originally set to close on a specific date, to give interested persons more time to submit their comments.